Agenda

schedule & speakers

Day 1

Thursday, June 20^th 2024

8h00

Registration and welcome coffee

8h45

Welcome Address - Einstein Auditorium

9h00

OPENING KEYNOTE LECTURES - Einstein Auditorium

Next generation bispecific antibodies and antibody fusion proteins for cancer immunotherapy

Christian Klein
Distinguished Scientist, is Department Head Cancer Immunotherapy Discovery 3, Head Oncology Programs & Site Head Roche Innovation Center Zurich
Roche pRED, Switzerland

Clinical development of bispecific antibodies and ADCs: toxicity mitigation and activity optimization strategies in expanded phase I trials

Elisa Fontana
MD, PhD, Hospital Medical Director
The Sarah Cannon Research Institute in London, UK

10h00

Coffee Break at Exhibition Hall

10h30

Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session I

KnotBodies: creating Ion Channel Modulating Antibodies by fusing Knottins in Antibody loops

Pedro Villar
Senior Scientist
Maxion Therapeutics, UK

From Sugars to Solutions: Advancing Cancer Therapeutics with Glycobiology

Paula Videira
Co-founder and CTO
CellmAbs
Associate Professor and Group Leader
UCIBIO, NOVA School of Science and Technology, NOVA University Lisbon, Portugal

Optimizing Discovery Strategies for TCR Bispecifics

Peter Molloy
Senior Fellow, Protein Engineering
Immunocore Ltd, UK

Leveraging cutting-edge DNA technologies to build precision libraries for antibody engineering

Radha Parmar
Science & Technology Consultant, Biologics - EMA
Twist Bioscience, USA

Antibody-based Cancer Therapies : latest developments - Barthez Auditorium

Bispecific Antibody Drug Conjugates (BsADCs): strategies and challenges

Alain Beck
Senior Director, Biologics CMC & developability
Pierre Fabre, France

Innovative cancer therapies based on first-in-class antibodies anti-GPCR drug conjugates

Aiphi Andrée Nguyen
CEO
Skymab Biotherapeutics, France

Merus Class of Bispecific ADC (ADClonicsTM) to Achieve Improved Binding Selectivity, Internalization and Tumor Cell Killing

Peter Lowe
Director Antibody Engineering
Merus, Netherlands

Comprehensive and Reliable Characterization of Antibody Therapeutics thanks to Kimialys's innovative SPR biochips

Claude Nogues
CSO & Co-founder
Kimialys, France

12h10

Lunch at Exhibition Hall

13h00

Workshop : How to analyze NGS antibody sequence data in PipeBio - Barthez Auditorium

Simit Patel
Senior Field Applications Scientist
PipeBio, Denmark

14h00

Paving the way for the next-generation of Antibodies & New Modalities - Einstein Auditorium

Session II

Exploiting the advances of soloMER biologics to deliver multi-functional products for autoimmune diseases and cancer

Caroline Barelle
CEO & founder
Elasmogen, UK

De novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization

Stefan Zielonka
Global Head of Antibody Discovery & Protein Engineering
Merck Healthcare KGaA
Professor of Biomolecular Immunotherapy
Technical University of Darmstadt, Germany

Avidity Engineering : a next frontier in the development of differentiating antibody therapeutics

Simone Oostindie
Director Research & Discovery
GYES, Netherlands

Targeting tumor microenvironment with human antibodies demonstrating improved developability properties

Anne Chevrel
Head of Discovery
Mabqi, France

Discovery and Development on Non-IgG based antibodies treatments - Barthez Auditorium

Using IgE based antibodies to treat cancer

Elizabeth Hardaker
VP of Biology
Epsilogen, UK

Engineered monoclonal IgA for the treatment of cancer

Mitchell Evers
Antibody Scientist
Utrecht University, Netherlands

Streamlining Therapeutic Antibody Development with a Homogeneous Bioluminescent Immunoassay for Signaling Pathway Analysis

Hicham Zegzouti
Senior Research Scientist - Group Leader
Promega, USA

Low-volume, automation friendly protein characterization

Sandra Flores
Field Applications Scientist
Unchained Labs, Germany

15h40

Coffee Break at Exhibition Hall

16h00

Pitch Session : Innovative Approaches and New trend Technologies - Einstein Auditorium

Assessing the immunomodulatory effects of Immune Checkpoint Antibodies using 3D cell co-culture models

Marcin Krzykawski
CEO
Real Research, Poland

Generation of nano-antibodies using extracellular vesicles for diagnostic purposes

Clara Bouyx
Post-Doc CNRS (Operations manager of the LabCom NVDIAG)
Laboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), France

APL-1030, a Novel High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation

Mathieu Cinier
CSO
Affilogic, France

A new technology for lysosomal targeted degradation of extracellular and membrane proteins: antibody engineering with mannose 6-phosphate analogues

Ilaria Basile
R&D manager
NanoMedSyn, France

Tumor associated macrophages targeting with a new specific monoclonal antibody

Mary Poupot
Researcher
Centre de Recherche en Cancérologie de Toulouse, Inserm, France

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Emmanuelle Liaudet-Coopman
Senior Scientist, DR2
Institut de Recherche en Cancérologie de Montpellier (IRCM)
Inserm U1194
Université Montpellier
Institut Régional du Cancer de Montpellier (ICM), France

Involvement of tumor microenvironment during targeted radionuclide therapy

Timothée David
Post-doctoral Researcher
Institut de Recherche en Cancérologie de Montpellier (IRCM)
Inserm U1194, France

Leveraging Photonic Integrated Circuit (PIC) technology to advance label-free biosensing for antibody screening and Point of Care diagnostics

Joël van der Vegt
Business Development Specialist
Delta Life Science, The Netherlands

Epitope mapping case studies by Deep Mutational Scanning

Raphael Sierocki
CEO/CSO
Deeptope, France

Workshop ENOTTA - European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA): Assembling a Multidisciplinary Puzzle - Barthez Auditorium

Olga Pitsillidou
Officer in the Pharmaceutical Care Team
Health Insurance Organization Cyprus (HIO) & University of Groningen

Azra Guzonjić
Teaching Assistant
University of Belgrade, Serbia

Ana Homšek
Teaching Assistant
University of Belgrade, Serbia

Georgios Kararigas
Professor
University of Iceland, Iceland

17h30

Round table - Enhancing Investment Understanding - Einstein Auditorium

Maxence de Vienne
Partner
Elyan

Lorenzo Pompei
General Delegate
Angels Santé

Adrien Clavairoly
Senior Associate
AdBio Partners

18h20

Investor's Pitch - Private session - Barthez Auditorium

19h00

Poster Presentation - Dinner Cocktail Reception at Exhibition Hall

20h30

Announcement of « BEST POSTER » by Biothérapie Innovation Occitanie

21h00

End of DAY 1

Day 2

Friday, June 21^st 2024

8h00

Welcome coffee

8h30

Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session I

Feasibility Assessment in Therapeutic Antibody Development: Leveraging PK/PD Modeling to Navigate Challenges and Mitigate Pitfalls

Lionel Renaud
PK/PD and Systems Pharmacology modeler
Lyo-X, Switzerland

From preclinical to clinical: PK-PD modelling of an antibody drug conjugate for therapeutic index prediction

Laurence del Frari
Pharmacokineticist, Modeling & Simulation
Pierre Fabre, France

Pharmacokinetics strategies to support First in Human studies for different biotherapeutic modalities

Antoine Deslandes
Global Head of Pharmacokinetics for Devices & Biotherapeutics
SANOFI, France

Non-oncology diseases/next generation of immunotherapies - Barthez Auditorium

The role of broadly neutralizing antibodies in HIV cure strategies

Ole Søgaard
Professor
Institut for Klinisk Medicin, Aarhus University, Denmark

Multimeric complexes to unlock the therapeutic potential of innate immunity

Carole Seguin-Devaux
Head of Research Unit
Luxemburg Institut of Health, Luxemburg

Antibody-based and CAR-T cell-based therapeutic approaches against SARS-CoV2 infections

Mireia Pelegrin
DR-CNRS, Head of Antibodies, Immunomodulation and Immunotherapy group
IRMB-INSERM U1183-CHU Saint Eloi, France

10h00

Coffee Break at Exhibition Hall

10h30

Efficacity and safety from preclinical to FIH trials - Einstein Auditorium

Session II

Case study on Clinical Dose Selection for TIGIT monospecific and bispecific antibodies

Pierre Ferre
VP Preclinical Development
Compugen Ltd, Israel

Alex Phipps
Executive Director. Head of Clinical Pharmacology and Quantitative Pharmacology (CPQP) - Oncology
AstraZeneca, UK

Next Generation Accelerated GMP Quality Control from Master Cell Banks to Drug Substance release testing

Philippe Grimm
Business Development & Marketing Director
SGS Vitrology, UK

Screening&Fluidics, a droplet microfluidics service provider for the discovery of your biological agent

Georges Gaudrialt
CEO
Screening & Fluidics, France

Novel PK Bioanalytical Approach Using a 1.5 plex Hybrid LC-MS/MS Assay for Quantification of Total Drug (ADC/ARC) and Total Ab for Support of Non-clinical and Clinical Trials

Dawn Dufield
Scientific Officer
KCAS Bio, USA

AI and Machine Learning for Antibody discovery and Optimization - Barthez Auditorium

Computational Approaches to Antibody Optimization and Humanization

Pietro Sormanni
Group Leader, Royal Society Univ. Research Fellow
University of Cambridge, UK

Towards an Integrated Platform for Antibody Discovery

Andrew Phillips
Head of Biologics AI Platform
SANOFI, UK

Unlocking the potential of artificial intelligence in antibody discovery

Thomas Bourquard
CSO and co-founder
MabSilico, France

12h00

Lunch at Exhibition Hall

13h00

Round Table "Nourrir l'innovation : Attirer et recruter les meilleurs talents dans l'industrie du Biomédicament" - Barthez Auditorium

14h00

Advancing new Antibodies approaches into the Clinic - Einstein Auditorium

First-in-Class anti-ChemR23 pro-resolutive agonist mAbs triggers the Resolution of chronic Inflammation

Nicolas Poirier
CEO
Ose Immunotherapeutics, France

Next-generation bispecific T cell engagers with built-in autoregulation to prevent treatment-related adverse events in adoptive T cell immunotherapies

Vincent Muczynski
Director of Biology
NovalGen Ltd
Research Fellow
University College London - Cancer Institut, UK

From Bench to Bedside : glenzocimab journey into the clinic

Elie Toledano
Head of Scientific Affairs and Business Intelligence
Acticor Biotech, France

Accelerating drug discovery using advanced antibody development platforms

Yu-Chih Lin
PhD. Technical specialist
Sino Biological, Germany

Innovative Approaches to overcome Bioprocessing Challenges - Barthez Auditorium

Therapeutic Protein Charge Variant Characterization with Intact Mass and Peptide Mapping Following Microgram Preparative Capillary Isoelectric Focusing Electrophoresis Fractionation

Géry Van Vyncht
Scientific Director
Quality Assistance, Belgium

Industrialization of biotechnology process with continuous DSP approach

David Balbuena
Director of Business Development
LFB Biomanufacturing, France

Smart Technologies and Smart Processes to serve Downstream Process Intensification Levels

Fabien Rousset
Principal Expert - Chromatography / DSP, BPS - Separation Technologies
SARTORIUS, France

Synthetic Biology tools to accelerate antibody development

Tatiana Konovalova
Bioinformatics R&D manager
Thermo Fisher Scientific, Germany

15h40

Closing Keynote - Einstein Auditorium

Bispecific Antibodies against infectious diseases

Luca Varani
Structural Biology Group Leader
Institute for Research in Biomedicine, Switzerland

16h10

Announcement of AIS2025

16h30

End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)6 26 33 63 21
ana-sofia.antunes@mabdesign.fr

Agenda

schedule & speakers

Day 1

Thursday, June 20th 2024

Day 2

Friday, June 21st 2024

SAVE THE DATE

Thursday, June 20^th 2024

Friday, June 21^st 2024